Article and Video CATEGORIES
David Spigel, Sarah Cannon Cancer Center, reviews how he discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.
[powerpress]
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi Stan! It is good to hear from you -- I am so very happy you are doing well. I agree with Janine that family and friends - our chosen family...
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Recent Comments
That's…
Hi Stan,
It's so good to hear you and yours are doing well and that you were able to spend time with both families for Thanksgiving. I know it meant a...